Press "Enter" to skip to content

U.S. benefits manager baulks after Novartis values gene therapy at $4-5 million

Just weeks after Novartis floated the idea that $4-5 million was fair value for its new gene therapy against a deadly neuromuscular disease, a major benefits manager is pushing back.

Original source:

Also Read:   Apple Watch detects irregular heart beat in large U.S. study